CL2016002483A1 - Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoide - Google Patents
Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoideInfo
- Publication number
- CL2016002483A1 CL2016002483A1 CL2016002483A CL2016002483A CL2016002483A1 CL 2016002483 A1 CL2016002483 A1 CL 2016002483A1 CL 2016002483 A CL2016002483 A CL 2016002483A CL 2016002483 A CL2016002483 A CL 2016002483A CL 2016002483 A1 CL2016002483 A1 CL 2016002483A1
- Authority
- CL
- Chile
- Prior art keywords
- pain
- encephalitis
- malaria
- oncology
- osteoporosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14163555 | 2014-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016002483A1 true CL2016002483A1 (es) | 2017-03-10 |
Family
ID=50424143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016002483A CL2016002483A1 (es) | 2014-04-04 | 2016-09-30 | Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoide |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20160376262A1 (enExample) |
| EP (1) | EP3126359A1 (enExample) |
| JP (1) | JP6654574B2 (enExample) |
| KR (1) | KR20160142365A (enExample) |
| CN (1) | CN106132958A (enExample) |
| AR (1) | AR099933A1 (enExample) |
| AU (1) | AU2015239539A1 (enExample) |
| CA (1) | CA2943013A1 (enExample) |
| CL (1) | CL2016002483A1 (enExample) |
| CR (1) | CR20160448A (enExample) |
| EA (1) | EA030116B1 (enExample) |
| IL (1) | IL247817A0 (enExample) |
| MA (1) | MA39843A (enExample) |
| MX (1) | MX2016012689A (enExample) |
| PE (1) | PE20161370A1 (enExample) |
| PH (1) | PH12016501865A1 (enExample) |
| SG (2) | SG11201608108SA (enExample) |
| TW (1) | TW201623276A (enExample) |
| WO (1) | WO2015150440A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA38404B1 (fr) | 2013-03-26 | 2017-09-29 | Hoffmann La Roche | Nouveaux dérivés de pyridine |
| MA39837B1 (fr) | 2014-04-04 | 2020-05-29 | H Lundbeck As | Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1 |
| MY195889A (en) * | 2015-12-09 | 2023-02-27 | Hoffmann La Roche | Phenyl Derivatives as Cannabinoid Receptor 2 Agonists |
| JP2019513700A (ja) | 2016-03-16 | 2019-05-30 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 殺有害生物剤及び植物保護剤としてのｎ−（シアノベンジル）−６−（シクロプロピル−カルボニルアミノ）−４−（フェニル）−ピリジン−２−カルボキサミド誘導体及び関連する化合物 |
| WO2018234284A1 (en) | 2017-06-20 | 2018-12-27 | F. Hoffmann-La Roche Ag | Pyridine derivatives |
| CN116640118B (zh) | 2018-06-27 | 2025-12-19 | 豪夫迈·罗氏有限公司 | 放射性标记的大麻素受体2配体 |
| CN119161323A (zh) * | 2018-06-27 | 2024-12-20 | 豪夫迈·罗氏有限公司 | 作为大麻素受体2的抑制剂的新型吡啶和吡嗪化合物 |
| CN112119068A (zh) | 2018-06-27 | 2020-12-22 | 豪夫迈·罗氏有限公司 | 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物 |
| WO2020002270A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2601575A1 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| FR2887550A1 (fr) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique |
| EP2155747B1 (en) * | 2007-05-10 | 2012-10-24 | GE Healthcare Limited | Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors |
| EP2311443A1 (en) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US9321727B2 (en) * | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| RS55951B1 (sr) * | 2012-12-07 | 2017-09-29 | Hoffmann La Roche | Derivati pirazina kao agonisti cb2 receptora |
| PL2928868T3 (pl) * | 2012-12-07 | 2017-12-29 | F.Hoffmann-La Roche Ag | Pirydyno-2-amidy użyteczne jako agoniści cb2 |
-
2015
- 2015-04-01 MX MX2016012689A patent/MX2016012689A/es unknown
- 2015-04-01 CA CA2943013A patent/CA2943013A1/en not_active Abandoned
- 2015-04-01 WO PCT/EP2015/057151 patent/WO2015150440A1/en not_active Ceased
- 2015-04-01 CN CN201580017199.1A patent/CN106132958A/zh active Pending
- 2015-04-01 PE PE2016001656A patent/PE20161370A1/es unknown
- 2015-04-01 EP EP15713492.5A patent/EP3126359A1/en not_active Withdrawn
- 2015-04-01 CR CR20160448A patent/CR20160448A/es unknown
- 2015-04-01 AR ARP150100985A patent/AR099933A1/es unknown
- 2015-04-01 MA MA039843A patent/MA39843A/fr unknown
- 2015-04-01 SG SG11201608108SA patent/SG11201608108SA/en unknown
- 2015-04-01 AU AU2015239539A patent/AU2015239539A1/en not_active Abandoned
- 2015-04-01 SG SG10201809066TA patent/SG10201809066TA/en unknown
- 2015-04-01 KR KR1020167030780A patent/KR20160142365A/ko not_active Withdrawn
- 2015-04-01 EA EA201691983A patent/EA030116B1/ru not_active IP Right Cessation
- 2015-04-01 JP JP2016560674A patent/JP6654574B2/ja not_active Expired - Fee Related
- 2015-04-02 TW TW104111026A patent/TW201623276A/zh unknown
-
2016
- 2016-09-09 US US15/260,826 patent/US20160376262A1/en not_active Abandoned
- 2016-09-14 IL IL247817A patent/IL247817A0/en unknown
- 2016-09-22 PH PH12016501865A patent/PH12016501865A1/en unknown
- 2016-09-30 CL CL2016002483A patent/CL2016002483A1/es unknown
-
2018
- 2018-07-24 US US16/044,320 patent/US20180327396A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201809066TA (en) | 2018-11-29 |
| KR20160142365A (ko) | 2016-12-12 |
| TW201623276A (zh) | 2016-07-01 |
| PH12016501865A1 (en) | 2016-12-19 |
| WO2015150440A1 (en) | 2015-10-08 |
| US20180327396A1 (en) | 2018-11-15 |
| EA201691983A1 (ru) | 2017-01-30 |
| EP3126359A1 (en) | 2017-02-08 |
| AU2015239539A1 (en) | 2016-09-29 |
| JP2017509676A (ja) | 2017-04-06 |
| CN106132958A (zh) | 2016-11-16 |
| SG11201608108SA (en) | 2016-10-28 |
| PE20161370A1 (es) | 2016-12-17 |
| MX2016012689A (es) | 2016-12-14 |
| EA030116B1 (ru) | 2018-06-29 |
| MA39843A (fr) | 2017-02-08 |
| IL247817A0 (en) | 2016-11-30 |
| CA2943013A1 (en) | 2015-10-08 |
| AR099933A1 (es) | 2016-08-31 |
| US20160376262A1 (en) | 2016-12-29 |
| JP6654574B2 (ja) | 2020-02-26 |
| CR20160448A (es) | 2016-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016002483A1 (es) | Compuestos derivdos de piridinpirazin-2-carboxamida, moduladores del cb2 proceso de preparacion composicion farmaceutica y su uso para el tratamiento o profilaxis del dolor, dolor neuropátíco, asma, osteoporosis, inflamación, enfermedades psiquiátricas, psicosis, oncología, encefalitis, malaria, alergia, trastornos inmunológicos, artritis reumatoide | |
| ECSP17047155A (es) | Productos farmacéuticos y composiciones líquidas estables de anticuerpos contra il-17 | |
| PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
| EP3256114A4 (en) | Treatment of osteoporosis | |
| NZ726859A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| ITUB20151922A1 (it) | Procedimento per la produzione di polietilene tereftalato modificato glicole da materie prime di riciclo | |
| GB201610056D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| CL2017000087A1 (es) | Un proceso novedoso para la purificación de rhu-gcsf | |
| IL268550B (en) | Purification of pleuromotilin | |
| PL3717457T3 (pl) | Sposób wytwarzania enzalutamidu z wykorzystaniem nowych związków pośrednich | |
| PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
| IN2015CH01182A (enExample) | ||
| GB201610055D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders and osteoarthritis | |
| MX2017005810A (es) | Nueva sintesis telescopica de 2-metoximetil-p-fenilenediamina. | |
| DK3326720T3 (da) | Fremgangsmåde til behandling af flerfase mineralske råmaterialer | |
| IL248055A0 (en) | Preparations of multimeric influenza proteins with multiple epitopes and their preparation | |
| CL2016002321A1 (es) | Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios. | |
| SI3250535T1 (sl) | Postopek za pripravo mnogogliničnega cementa | |
| MX2017005809A (es) | Nueva sintesis telescopica de 2-metoximetil-p-fenilenediamina. | |
| TN2017000088A1 (en) | Synthesis of ent-progesterone and intermediates thereof. | |
| MX375918B (es) | Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis. | |
| IL263416A (en) | Modification of transgenic influenza hemagglutinin polypeptides | |
| IL263468A (en) | New molecules to treat inflammation | |
| PL3164110T3 (pl) | Kompozycje farmaceutyczne do leczenia łuszczycy | |
| IS2977B (is) | Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni |